LobbyingAcesso Biologics lobbying by quarter
Acesso Biologics's latest lobbying report covers Q2 2026, at $60K. The four quarters Q4 2025–Q3 2026 total $180K. Its first report covers Q1 2025; the issues it reports most are Medicare/Medicaid.
Acesso Biologics
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $180K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q1 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2025 | $30K | 1 |
| Q2 2025 | $50K | 1 |
| Q3 2025 | $50K | 1 |
| Q4 2025 | $60K | 1 |
| Q1 2026 | $60K | 1 |
| Q2 2026 | $60K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Medicare and Medicaid$310K · 6 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES6 reports
- SENATE6 reports
- Centers For Medicare and Medicaid Services (CMS)4 reports
- Health & Human Services, Dept of (HHS)4 reports
- Office of Management & Budget (OMB)4 reports
Firms it paid
| Firm | ||
|---|---|---|
| The McManus Group | $310K | 6 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | The McManus Group | $60K |
| 04/20for Q1 | The McManus Group | $60K |
| 01/20for Q4 2025 | The McManus Group | $60K |
| 25/10/20for Q3 2025 | The McManus Group | $50K |
| 25/08/04for Q2 2025 | The McManus Group | $50K |
| 25/04/21for Q1 2025 | The McManus Group | $30K |
| 25/02/21for Q1 2025 | The McManus Group | Under $5,000 |